Health breakthroughs and money matters, in plain words

Home » FDA approves Novo Nordisk’s Sogroya as first weekly growth hormone for Turner syndrome

FDA approves Novo Nordisk’s Sogroya as first weekly growth hormone for Turner syndrome

By

–

FDA approves Novo Nordisk's Sogroya as first weekly growth hormone for Turner syndrome

PLAINSBORO, November 21, 2026 — Families of children with Turner syndrome now have a new treatment option. The FDA has approved Sogroya, a once-weekly injection, for kids aged 2.5 and older with growth failure linked to this genetic condition.

A Weekly Alternative to Daily Shots

This approval means children can now receive their growth hormone treatment just once a week instead of daily injections. For families, this translates to 313 fewer injection days each year, according to Novo Nordisk, the drug’s maker.

Turner syndrome affects about one in 2,000 newborn girls, often leading to short stature and other developmental challenges. Growth hormone therapy is a standard treatment, but daily injections can be a burden for children and their caregivers.

Comparable Growth, Fewer Injections

The FDA’s decision was based on the REAL8 trial, which compared Sogroya to daily growth hormone injections. Over 52 weeks, children on Sogroya grew an average of 8.9 cm, while those on daily injections grew 9.7 cm. Novo Nordisk says this shows comparable growth rates.

Dr. Aristides Maniatis, a trial investigator, highlights the convenience: “This weekly option may make the treatment routine simpler for families, fitting more easily into their daily lives.”

What This Means for Patients

Sogroya is already approved for other growth-related conditions, including growth hormone deficiency and Noonan syndrome. This new approval adds Turner syndrome to the list, offering a fifth treatment option for pediatric growth disorders.

Common side effects in the trial included respiratory and ear infections, fever, diarrhea, and vomiting. A two-year extension of the study is underway to monitor long-term safety.

Market Reaction Muted

Despite the approval, Novo Nordisk’s shares dipped 1.3% to 2.1% on the news. The company’s stock has been under pressure, down nearly 27% in 2026, while rival Eli Lilly has seen gains of over 25%.

For families managing Turner syndrome, this weekly option could mean less disruption and more normalcy. As always, consult your doctor to discuss the best treatment plan for your child.

Sources

Photo: Kwameghana (CC BY-SA 4.0)

Get breaking stories first on our Telegram channel.

More stories by

Most read

Health & Medicine

Personal Finance

Cancer News

Health News